Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

Fig. 3

Comparison of survival distributions by HED levels in different subpopulations in the PUCH cohort. a, b Kaplan-Meier survival analysis comparing the OS (a) and PFS (b) curves between the high-HLA-B HED and low-HLA-B HED subgroups of patients with MSI-H GI cancer (n = 15). c, d Kaplan-Meier survival analysis comparing the OS (c) and PFS (d) curves between the high-HLA-B HED and low-HLA-B HED subgroups of patients with MSS GI cancer (n = 61). For the MSS subgroup, only 60 patients had PFS information (the subgroup survival analysis was not performed in the MSK GI cohort since the MSI status was not available when downloaded)

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us